Rilonacept

Phase 3

Regeneron Pharmaceuticals, Inc. (REGN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Gout

View Full Landscape

Drug Information

Target Indication

Gout

Clinical Trial

NCT00958438

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Rilonacept FGK Representative Service GmbH

Treatment of idiopathic pericarditis

Orphan

View on EMA

EMA10/23/2009

Rilonacept Regeneron (previously Arcalyst)

Rilonacept Regeneron is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), in adults and children aged 12 years and older.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AlirocumabPhase 3

Homozygous Familial Hypercholesterolemia

StatinPhase 3

Hypercholesterolemia